ArticleUpdates in surgery2026
Preservation of EUS-guided gastrojejunostomy LAMS during pancreaticoduodenectomy: a paradigm shift in the surgical management of borderline resectable pancreatic cancer.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) with lumen-apposing metal stents (LAMS) is increasingly employed for palliation in pancreatic ductal adenocarcinoma (PDAC). We report the first European case in which a EUS-GJ LAMS was preserved and functionally integrated during pancreaticoduodenectomy (PD), supporting the concept that endoscopic bypass can be part of a curative surgical pathway. A 59-year-old male with borderline resectable PDAC and failed ERCP underwent sequential endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) and gastrojejunostomy with LAMS. After completing a full course of neoadjuvant chemotherapy and showing tumor regression, he underwent PD with en bloc portal vein resection. The preexisting LAMS was intraoperatively preserved and incorporated as the definitive gastrojejunostomy. Outcome: The patient had an uneventful recovery. Final pathology confirmed ypT1c N0 M0 R0 PDAC. At 6-month follow-up, he was recurrence-free. EUS-GJ with LAMS can be successfully preserved and integrated during PD, suggesting a potential shift from exclusively palliative use to potentially curative indications. Further investigation in multidisciplinary settings is warranted.
Indexed as
Identifiers
40875165What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.